The most-clicked news item for Tuesday was “Boehringer to cut costs by 15%.” After announcing disappointing financial results for the first half of 2014, Boehringer Ingelheim is apparently planning layoffs. It is not yet known whether these will be limited to Germany, or throughout BI’s international workforce.
The second most popular news item was a Fierce Pharma Marketing piece, “Communiqué to sales reps: With today's docs, it's the medium and the message,” which details the results of a ZS Associates annual report of the state of the pharma sales rep in the US, including physician access and rep effectiveness.
The third most-clicked item on Tuesday was “From Riches to Rags: Vertex Discontinues Incivek as Sales Evaporate,” from WSJ’s Pharmalot. The article details the fall of Vertex’s previously-lauded hepatitis C treatment Incivek, which is being discontinued in October of this year.
The fourth most popular news link was Motley Fool’s “5 Things Pfizer Inc.'s Management Wants You to Know.” The article is based on quotes from the most recent earnings conference call, and discusses stock buybacks, generics, emerging markets, palbociclib, and M&A.